-
Published17/06/2025
-
Today12/07/2025
-
Deadline17/07/2025
-
Opening of tenders17/07/2025
Utilities
- indicates text translated automatically in your browsing language
Purchase of alteplase, tobramycin and zoledronic acid Text automatically translated in your browsing language Automatically translated
The object of the public procurement is the purchase of medicinal products containing alteplase, tobramycin and zoledronic acid. For a more detailed description of the subject matter of the public procurement, see Annex 1 – Technical specifications. As a result of the public procurement, a framework contract will be awarded to one tenderer for each part of the public procurement for a period of 12 months (including the sales period of the framework contract starting from the award of lot 1 and starting from 01.11.2025 in lots 2 and 3). Separate contracts under framework contracts are not signed, but the framework contract is executed on the basis of orders. The unit prices of the medicinal product indicated in the tender shall be valid for the entire duration of the framework contract. / Grounds for exclusion and selection criteria: See procurement documents Text automatically translated in your browsing language Automatically translated
https://riigihanked.riik.ee/rhr-web/#/procurement/8961584/tenders
https://riigihanked.riik.ee/rhr-web/#/procurement/8961584/tenders
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.